Rank,Term name,P-value,Z-score,Combined score,Overlapping genes,Adjusted p-value,Old p-value,Old adjusted p-value,gene count
1,Cytoplasmic Ribosomal Proteins WP477,7.177183009612212e-32,31.274251953497238,2242.73340188417,"['RPL30', 'RPL34', 'RPLP1', 'RPL11', 'RPL10A', 'RPL9', 'RPS15', 'RPS14', 'RPS15A', 'RPL18A', 'RPL35', 'RPL38', 'RPS27A', 'RPL39', 'RPS10', 'RPS13', 'RPS12', 'RPL41', 'RPL21', 'RPS8', 'RPL35A', 'RPS3A', 'RPS26', 'RPS28', 'RPS27', 'RPS29', 'RPL24', 'RPL26', 'FAU', 'RPL29', 'RPS21', 'RPS24']",8.827935101823021e-30,0,0,32
2,Electron Transport Chain (OXPHOS system in mitochondria) WP111,2.005711515258573e-24,25.139705882352942,1371.774281324546,"['COX7B', 'UQCRB', 'COX4I1', 'COX17', 'NDUFB2', 'NDUFB1', 'COX7A2', 'UQCR11', 'UQCR10', 'COX5B', 'COX7A1', 'UQCRH', 'ATP5MC1', 'UQCRFS1', 'ATP5MG', 'ATP5MF', 'COX8A', 'NDUFA7', 'ATP5PD', 'NDUFA5', 'NDUFA1', 'COX6C', 'ATP5F1E', 'COX6B1', 'UQCRQ', 'NDUFS6']",1.2335125818840226e-22,0,0,26
3,Nonalcoholic fatty liver disease WP4396,1.4638469104823968e-15,12.28485576923077,419.6225229955453,"['COX8A', 'NDUFA13', 'COX7B', 'NDUFA7', 'UQCRB', 'NDUFA5', 'COX4I1', 'NDUFB2', 'NDUFA1', 'NDUFB1', 'COX7A2', 'UQCR11', 'UQCR10', 'COX5B', 'COX6C', 'COX7A1', 'UQCRH', 'COX6B1', 'UQCRQ', 'NDUFS6', 'CYCS', 'UQCRFS1']",6.001772332977827e-14,0,0,22
4,Mitochondrial CIV Assembly WP4922,4.132329522315302e-10,23.384090909090908,505.2602775315954,"['COX8A', 'COX7B', 'COX4I1', 'COX17', 'COX7A2', 'COX14', 'COX5B', 'COX6C', 'PET117', 'COX6B1']",1.2706913281119554e-08,0,0,10
5,Oxidative phosphorylation WP623,5.1447497664884164e-08,12.61916461916462,211.78370468340657,"['NDUFA7', 'ATP5PD', 'NDUFA5', 'NDUFS6', 'NDUFB2', 'NDUFB1', 'ATP5MG', 'ATP5MF', 'ATP5F1E', 'ATP5MC1']",1.2656084425561505e-06,0,0,10
6,Mitochondrial complex III assembly WP4921,1.528366029392886e-07,39.420918367346935,618.6678104610953,"['UQCRB', 'UQCRQ', 'UQCRFS1', 'UQCR11', 'UQCR10', 'UQCRH']",3.1331503602554163e-06,0,0,6
7,Mitochondrial complex I assembly model OXPHOS system WP4324,2.5707138993686965e-05,9.486283302558691,100.2580790825088,"['NDUFA13', 'NDUFA7', 'NDUFA5', 'NDUFS6', 'NDUFB2', 'NDUFA1', 'NDUFB1']",0.00045171115660335673,0,0,7
8,Cytosine methylation WP3585,0.006713001566284923,22.598684210526315,113.0772418481552,"['TDG', 'TET1']",0.1032123990816307,0,0,2
9,Eukaryotic Transcription Initiation WP405,0.03460454947713889,4.528193832599119,15.231803101629083,"['POLR2I', 'GTF2E1', 'POLR2K']",0.4729288428542315,0,0,3
10,Overview of leukocyte-intrinsic Hippo pathway functions WP4542,0.0635721283228769,5.31062951496388,14.633865214927354,"['LPL', 'FOXO4']",0.6859198909508994,0,0,2
11,Macrophage markers WP4146,0.06405836580495892,22.504366812227076,61.841114352077554,['CD74'],0.6859198909508994,0,0,1
12,Proteasome Degradation WP183,0.06691901375130727,3.39284140969163,9.175166502039485,"['PSMB6', 'H2AFZ', 'PSMB10']",0.6859198909508994,0,0,3
13,Fatty acid beta-oxidation WP143,0.08233258257152816,4.512719298245614,11.268207512862002,"['ECI1', 'LPL']",0.7423037241224386,0,0,2
14,Composition of Lipid Particles WP3601,0.08448985477816373,15.00145560407569,37.07045418225288,['LPL'],0.7423037241224386,0,0,1
15,Arachidonate Epoxygenase / Epoxide Hydrolase WP678,0.1044772281566612,11.25,25.411344116625795,['COX8A'],0.803168691454333,0,0,1
16,Cytokines and Inflammatory Response WP530,0.1044772281566612,11.25,25.411344116625795,['PDGFA'],0.803168691454333,0,0,1
17,Alzheimer's disease WP2059,0.11817638934685934,2.606828193832599,5.567082192102197,"['ATP5MD', 'LPL', 'CYCS']",0.8397639262920631,0,0,3
18,Copper homeostasis WP3286,0.12392257773842326,3.469298245614035,7.244235704526285,"['COX17', 'ATOX1']",0.8397639262920631,0,0,2
19,"Metabolic pathway of LDL, HDL and TG, including diseases WP4522",0.14315786441740858,7.498544395924308,14.575725416021644,['LPL'],0.8397639262920631,0,0,1
20,Androgen receptor signaling pathway WP138,0.14792144723117726,2.3357891538812092,4.4638657067434835,"['SUMO1', 'BAG1', 'RNF4']",0.8397639262920631,0,0,3
21,Rett syndrome causing genes WP4312,0.17716278790108408,2.731525784157363,4.727414152825732,"['ACTL6B', 'GPS2']",0.8397639262920631,0,0,2
22,Mitochondrial LC-Fatty Acid Beta-Oxidation WP368,0.19808159837552675,4.9975739932071805,8.091453210967428,['ECI1'],0.8397639262920631,0,0,1
23,Genotoxicity pathway WP4286,0.20094557437746086,2.503167641325536,4.016886135707813,"['PLK3', 'RPS27']",0.8397639262920631,0,0,2
24,Kallmann's Syndrome WP5074,0.2155990238122852,4.497379912663756,6.900487263165942,['ANOS1'],0.8397639262920631,0,0,1
25,Triacylglyceride synthesis WP325,0.2155990238122852,4.497379912663756,6.900487263165942,['LPL'],0.8397639262920631,0,0,1
26,Selenium Micronutrient Network WP15,0.2169990151275001,2.370960295475531,3.62250123917422,"['SELENOW', 'SELENOH']",0.8397639262920631,0,0,2
27,7q11.23 copy number variation syndrome WP4932,0.22476091371574347,1.8790381791483113,2.8048742018645787,"['VPS37B', 'ATP5F1E', 'ATP5MC1']",0.8397639262920631,0,0,3
28,TP53 network WP1742,0.23273541900403158,4.088130210400953,5.959892938173403,['SUMO1'],0.8397639262920631,0,0,1
29,Statin inhibition of cholesterol production WP430,0.2494990363922373,3.747088791848617,5.202084216390825,['LPL'],0.8397639262920631,0,0,1
30,Nanomaterial induced apoptosis WP2507,0.2494990363922373,3.747088791848617,5.202084216390825,['CYCS'],0.8397639262920631,0,0,1
31,AGE/RAGE pathway WP2324,0.2656574587019493,2.046451355661882,2.7126685792649923,"['CYCS', 'FOXO4']",0.8397639262920631,0,0,2
32,Apoptosis Modulation by HSP70 WP384,0.2819400618157379,3.211166562694947,4.0655320346878785,['CYCS'],0.8397639262920631,0,0,1
33,MTHFR deficiency WP4288,0.2819400618157379,3.211166562694947,4.0655320346878785,['CYCS'],0.8397639262920631,0,0,1
34,Mesodermal commitment pathway WP2857,0.2835204415643522,1.6482754915654882,2.0776035463506726,"['CCDC6', 'TET1', 'RPL38']",0.8397639262920631,0,0,3
35,Canonical and non-canonical Notch signaling WP3845,0.2976331002405667,2.996797671033479,3.6318003923579703,['MFAP1'],0.8397639262920631,0,0,1
36,FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma WP4553,0.2976331002405667,2.996797671033479,3.6318003923579703,['H2AFZ'],0.8397639262920631,0,0,1
37,Hair Follicle Development: Organogenesis - Part 2 of 3 WP2839,0.2976331002405667,2.996797671033479,3.6318003923579703,['PDGFA'],0.8397639262920631,0,0,1
38,DNA Repair Pathways Full Network WP4946,0.3014444937598737,1.589634620367971,1.9062411622323303,"['CENPX', 'TDG', 'RAD23B']",0.8397639262920631,0,0,3
39,VEGFA-VEGFR2 Signaling Pathway WP3888,0.30956512364802014,1.2674569306148253,1.4862032579506301,"['RPL18A', 'SSR4', 'FLII', 'CYCS', 'RPL26', 'FOXO4', 'RPL10A', 'TMSB10']",0.8397639262920631,0,0,8
40,miRNA regulation of p53 pathway in prostate cancer WP3982,0.31298462902062935,2.8092248908296944,3.263198999223899,['SIAH1'],0.8397639262920631,0,0,1
41,Retinoblastoma gene in cancer WP2446,0.3143371509278191,1.7998245614035089,2.0829174188880133,"['H2AFZ', 'CCDC6']",0.8397639262920631,0,0,2
42,Monoamine GPCRs WP58,0.32800204829585483,2.6437194965322375,2.9470477786971436,['HRH1'],0.8397639262920631,0,0,1
43,Fluoropyrimidine Activity WP1601,0.32800204829585483,2.6437194965322375,2.9470477786971436,['TDG'],0.8397639262920631,0,0,1
44,16p11.2 proximal deletion syndrome WP4949,0.3384426562532811,1.6974511751075803,1.8390196325072692,"['SIAH1', 'CCDC6']",0.8397639262920631,0,0,2
45,Sphingolipid pathway WP1422,0.3426925984713018,2.496603590490053,2.6736663322739833,['GBA2'],0.8397639262920631,0,0,1
46,Differentiation Pathway WP2848,0.3426925984713018,2.496603590490053,2.6736663322739833,['PDGFA'],0.8397639262920631,0,0,1
47,Development of ureteric collection system WP5053,0.3711212756626163,2.246506550218341,2.226796558143445,['ANOS1'],0.8397639262920631,0,0,1
48,Nucleotide-binding Oligomerization Domain (NOD) pathway WP1433,0.3711212756626163,2.246506550218341,2.226796558143445,['NDUFA13'],0.8397639262920631,0,0,1
49,Extracellular vesicle-mediated signaling in recipient cells WP2870,0.3711212756626163,2.246506550218341,2.226796558143445,['MFGE8'],0.8397639262920631,0,0,1
50,Ciliary landscape WP4352,0.3752799950190545,1.304476080543799,1.2784946716074854,"['NDUFA5', 'MFAP1', 'MYL6B', 'COX6C']",0.8397639262920631,0,0,4
51,Lung fibrosis WP3624,0.38487311573178923,2.1393221043876065,2.0427136737703444,['PDGFA'],0.8397639262920631,0,0,1
52,CAMKK2  Pathway WP4874,0.38487311573178923,2.1393221043876065,2.0427136737703444,['FIS1'],0.8397639262920631,0,0,1
53,Vitamin A and carotenoid metabolism WP716,0.38487311573178923,2.1393221043876065,2.0427136737703444,['LPL'],0.8397639262920631,0,0,1
54,Endothelin Pathways WP2197,0.38487311573178923,2.1393221043876065,2.0427136737703444,['RIIAD1'],0.8397639262920631,0,0,1
55,PI3K-AKT-mTOR signaling pathway and therapeutic opportunities WP3844,0.38487311573178923,2.1393221043876065,2.0427136737703444,['FOXO4'],0.8397639262920631,0,0,1
56,Tumor suppressor activity of SMARCB1 WP4204,0.39832551938812777,2.041881699086939,1.879522946093815,['ACTL6B'],0.8397639262920631,0,0,1
57,Pyrimidine metabolism WP4022,0.401274658150861,1.4736842105263157,1.34563454139669,"['POLR2I', 'POLR2K']",0.8397639262920631,0,0,2
58,Base Excision Repair WP4752,0.424357845911852,1.8713609898107715,1.6040898513284634,['TDG'],0.8397639262920631,0,0,1
59,Oxidative Damage WP3941,0.424357845911852,1.8713609898107715,1.6040898513284634,['CYCS'],0.8397639262920631,0,0,1
60,Phosphoinositides metabolism WP4971,0.424357845911852,1.8713609898107715,1.6040898513284634,['SACM1L'],0.8397639262920631,0,0,1
61,miRNA regulation of prostate cancer signaling pathways WP3981,0.4369503356316426,1.7963318777292576,1.4872473602911738,['PDGFA'],0.8397639262920631,0,0,1
62,Neural Crest Cell Migration during Development WP4564,0.4369503356316426,1.7963318777292576,1.4872473602911738,['EPHB3'],0.8397639262920631,0,0,1
63,Fas ligand pathway and stress induction of heat shock proteins WP314,0.4369503356316426,1.7963318777292576,1.4872473602911738,['CYCS'],0.8397639262920631,0,0,1
64,Parkinson's disease pathway WP2371,0.4369503356316426,1.7963318777292576,1.4872473602911738,['CYCS'],0.8397639262920631,0,0,1
65,Neural Crest Cell Migration in Cancer WP4565,0.4613183741702728,1.6629467895843442,1.2865668176022564,['EPHB3'],0.8597296973173266,0,0,1
66,NO/cGMP/PKG mediated Neuroprotection WP4008,0.4613183741702728,1.6629467895843442,1.2865668176022564,['CYCS'],0.8597296973173266,0,0,1
67,Amyotrophic lateral sclerosis (ALS) WP2447,0.48463618086142723,1.5479596446318327,1.1212751134389602,['NEFH'],0.8723594333153093,0,0,1
68,Cytosolic DNA-sensing pathway WP4655,0.48463618086142723,1.5479596446318327,1.1212751134389602,['POLR2K'],0.8723594333153093,0,0,1
69,EGF/EGFR signaling pathway WP437,0.4943865452354454,1.1413798252818637,0.8040308505867544,"['NDUFA13', 'NEDD8', 'FOXO4']",0.8723594333153093,0,0,3
70,PPAR signaling pathway WP3942,0.5069488301158538,1.4478095506409354,0.9835624792786453,['LPL'],0.8723594333153093,0,0,1
71,Modulators of TCR signaling and T cell activation WP5072,0.5177417774960779,1.4024290393013101,0.9231891088161945,['ZFP36L1'],0.8723594333153093,0,0,1
72,PDGF Pathway WP2526,0.5177417774960779,1.4024290393013101,0.9231891088161945,['PDGFA'],0.8723594333153093,0,0,1
73,Glucocorticoid Receptor Pathway WP2880,0.5177417774960779,1.4024290393013101,0.9231891088161945,['MFGE8'],0.8723594333153093,0,0,1
74,Aryl Hydrocarbon Receptor Netpath WP2586,0.5282994700490237,1.359798861982268,0.8676767454393502,['LPL'],0.8781193894058096,0,0,1
75,Nucleotide Excision Repair WP4753,0.5386270138061626,1.3196763421525814,0.8165259089771374,['RAD23B'],0.8833483026421066,0,0,1
76,IL-4 signaling pathway WP395,0.5586115291695151,1.2461183891314895,0.7256159670164523,['HRH1'],0.8923275076344201,0,0,1
77,Exercise-induced Circadian Regulation WP410,0.5586115291695151,1.2461183891314895,0.7256159670164523,['SUMO1'],0.8923275076344201,0,0,1
78,IL-18 signaling pathway WP4754,0.598030535715718,0.9740471174104578,0.5007707369155867,"['NRN1', 'COX17', 'CYCS']",0.9033801525272527,0,0,3
79,MECP2 and Associated Rett Syndrome WP3584,0.6135393801590494,1.0674776460802662,0.5214743882809081,['TET1'],0.9033801525272527,0,0,1
80,Translation Factors WP107,0.6135393801590494,1.0674776460802662,0.5214743882809081,['EEF1B2'],0.9033801525272527,0,0,1
81,DNA damage response WP707,0.6135393801590494,1.0674776460802662,0.5214743882809081,['CYCS'],0.9033801525272527,0,0,1
82,Association Between Physico-Chemical Features and Toxicity Associated Pathways WP3680,0.6220079060687423,1.042551030770793,0.49500581035168906,['NEFH'],0.9033801525272527,0,0,1
83,miRNA regulation of DNA damage response WP1530,0.6220079060687423,1.042551030770793,0.49500581035168906,['CYCS'],0.9033801525272527,0,0,1
84,Integrated breast cancer pathway WP1984,0.6291541276167677,0.9431209602954755,0.43702246287267205,"['PLK3', 'FAU']",0.9033801525272527,0,0,2
85,MET in type 1 papillary renal cell carcinoma WP4205,0.6302916492609377,1.0187574434299325,0.47023055390521623,['RPL11'],0.9033801525272527,0,0,1
86,Sterol regulatory element-binding proteins (SREBP) signaling WP1982,0.6383946244860679,0.9960213488597768,0.44701303990005764,['LPL'],0.9033801525272527,0,0,1
87,Acute viral myocarditis WP4298,0.646320759531693,0.9742737801404975,0.42523091702172233,['CYCS'],0.9033801525272527,0,0,1
88,Parkin-Ubiquitin Proteasomal System pathway WP2359,0.646320759531693,0.9742737801404975,0.42523091702172233,['SIAH1'],0.9033801525272527,0,0,1
89,Thyroid hormones production and their peripheral downstream signaling effects WP4746,0.6834304607172652,0.8783286240260296,0.3343185473733522,['ACTL6B'],0.9235047630945772,0,0,1
90,Apoptosis WP254,0.6903734071020158,0.861353711790393,0.3191510668200862,['CYCS'],0.9235047630945772,0,0,1
91,Joubert Syndrome WP4656,0.7038077228857896,0.829289988678635,0.2912881757201308,['ARL3'],0.9235047630945772,0,0,1
92,Chromosomal and microsatellite instability in colorectal cancer  WP4216,0.7038077228857896,0.829289988678635,0.2912881757201308,['CYCS'],0.9235047630945772,0,0,1
93,Ras signaling WP4223,0.7285885930620969,0.7775743707093822,0.24621585345336477,"['GNB4', 'FOXO4']",0.9235047630945772,0,0,2
94,Non-small cell lung cancer WP4255,0.7289598990177515,0.7717964162023792,0.24399306148589964,['CYCS'],0.9235047630945772,0,0,1
95,Glioblastoma signaling pathways WP2261,0.7349082665469198,0.7586411072459478,0.23366874017614536,['FOXO4'],0.9235047630945772,0,0,1
96,22q11.2 copy number variation syndrome WP4657,0.7407266427884531,0.745924308588064,0.22386950736989153,['MRPL40'],0.9235047630945772,0,0,1
97,Apoptosis Modulation and Signaling WP1772,0.7407266427884531,0.745924308588064,0.22386950736989153,['CYCS'],0.9235047630945772,0,0,1
98,"GPCRs, Class A Rhodopsin-like WP455",0.7519846745753538,0.7217213692069305,0.20571897898536845,['HRH1'],0.9235047630945772,0,0,1
99,EGFR Tyrosine Kinase Inhibitor Resistance WP4806,0.7574298047221372,0.7101961599778194,0.1973098312081017,['PDGFA'],0.9235047630945772,0,0,1
100,Small cell lung cancer WP4658,0.7679655383270968,0.6882096069868996,0.1816945065704806,['CYCS'],0.9235047630945772,0,0,1
101,Ebola Virus Pathway on Host WP4217,0.7679655383270968,0.6882096069868996,0.1816945065704806,['MFGE8'],0.9235047630945772,0,0,1
102,Thermogenesis WP4321,0.7829208555569283,0.6576547649627537,0.16094368541987872,['ACTL6B'],0.9235047630945772,0,0,1
103,NRF2 pathway WP2884,0.7876895134363696,0.6480602493513069,0.15466041142822717,['SLC5A3'],0.9235047630945772,0,0,1
104,Genes related to primary cilium development (based on CRISPR) WP4536,0.7876895134363696,0.6480602493513069,0.15466041142822717,['ARL3'],0.9235047630945772,0,0,1
105,ESC Pluripotency Pathways WP3931,0.7969161701198965,0.6296820222645919,0.14294146334237098,['PDGFA'],0.9235047630945772,0,0,1
106,Metapathway biotransformation Phase I and II WP702,0.8100128538926071,0.6039773397852001,0.12726114348852022,['KCNAB3'],0.9235047630945772,0,0,1
107,Adipogenesis WP236,0.826176018887237,0.5727802037845706,0.10937090800320871,['LPL'],0.9235047630945772,0,0,1
108,Endoderm differentiation WP2853,0.826176018887237,0.5727802037845706,0.10937090800320871,['TET1'],0.9235047630945772,0,0,1
109,Chemokine signaling pathway WP3929,0.8512357999296695,0.525250449524788,0.08460004305181998,['GNB4'],0.9235047630945772,0,0,1
110,mRNA Processing WP411,0.8545090584557115,0.5190921092718594,0.08161590530828278,['SRSF9'],0.9235047630945772,0,0,1
111,Nuclear Receptors Meta-Pathway WP2882,0.8586510513811528,0.5784347231715653,0.08814920962585103,"['MFGE8', 'SLC5A3']",0.9235047630945772,0,0,2
112,Angiopoietin Like Protein 8 Regulatory Pathway WP3915,0.8639047607092625,0.5014474265247044,0.07335812145950744,['LPL'],0.9235047630945772,0,0,1
113,Regulation of Actin Cytoskeleton WP51,0.872696153782765,0.4849534839567116,0.06603506457207763,['PDGFA'],0.9235047630945772,0,0,1
114,TGF-beta Signaling Pathway WP366,0.8754990902250673,0.4796919753955956,0.0637804045640773,['SUMO1'],0.9235047630945772,0,0,1
115,Calcium Regulation in the Cardiac Cell WP536,0.8861095784046422,0.45973078827713504,0.055588191205274196,['GNB4'],0.9235047630945772,0,0,1
116,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway WP3932,0.8893763061327302,0.5295008354218881,0.062075946537526516,"['GNB4', 'PDGFA']",0.9235047630945772,0,0,2
117,PI3K-Akt signaling pathway WP4172,0.8932247592126089,0.5231682146542828,0.059074606077785904,"['GNB4', 'PDGFA']",0.9235047630945772,0,0,2
118,Myometrial relaxation and contraction pathways WP289,0.8934720878719892,0.44580786026200875,0.05021587939154307,['GNB4'],0.9235047630945772,0,0,1
119,Hepatitis B infection WP4666,0.8934720878719892,0.44580786026200875,0.05021587939154307,['CYCS'],0.9235047630945772,0,0,1
120,Circadian rhythm related genes WP3594,0.9025567016312137,0.4284934497816594,0.04393076108805273,['RPS27A'],0.925120619171994,0,0,1
121,Ciliopathies WP4803,0.9362223167297272,0.3616288564632371,0.023832178028372952,['ARL3'],0.9506904692735944,0,0,1
122,Focal Adhesion WP306,0.942961278466492,0.3473321506550218,0.020398837792032082,['PDGFA'],0.9506904692735944,0,0,1
123,MAPK Signaling Pathway WP382,0.975632199549054,0.2668227495133372,0.0065824127206101195,['PDGFA'],0.975632199549054,0,0,1
